Jounce Therapeutics, Celgene deal

Jounce granted Celgene options to license multiple immuno-oncology programs from Jounce, including lead candidate JTX-2011. Jounce will receive $225

Read the full 198 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE